(42.0%). A total of 272 patients (75.6%) had available BMI data, which ranged between 17.5 and 52.6, without significant differences between the two groups (p¼0.1). ADT was administered only to 108 patients (30%), including all individuals diagnosed with PSA > 20 ng/mL. Median follow-up was 72 months. Overall, BF-free survival rates at 96 months was 79.6% (95% CI: 72.3-87.6%) in hypogonadal vs. 65.1% (95% CI: 55.3-76.7%) in non-hypogonadal individuals (p¼0.042). In multivariable Cox regression analyses, BST < 11 nmol/L was associated with a significantly reduced risk of BF (HR: 0.50; CI 0.30-0.83; p ¼ 0.007). After 10,000 bootstrap resamples, virtually the same results were recorded.
INTRODUCTION AND OBJECTIVES:
Transrectal prostate brachytherapy is a common outpatient procedure for the treatment of clinically-localized prostate cancer. While the long-term morbidity and toxicities of prostate brachytherapy are widely published, rates of shortterm complications are largely unknown. We aim to determine the incidence of acute hospital visits for treatment-related complications of outpatient prostate brachytherapy and to identify associated risk favors.
METHODS: Patients who underwent prostate brachytherapy (CPT code 55875) for prostate cancer (ICD9 code 185) in an ambulatory surgery setting were identified in the Healthcare Cost and Utilization Project (HCUP) State Ambulatory Surgery Database for California between 2007-2011. Emergency department visits and inpatient admissions within 30 days of treatment were determined from the California HCUP State Emergency Department Database and State Inpatient Database, respectively. Risk factor analysis was performed using multivariate logistic regression.
RESULTS: Over five years, 8,188 patients underwent brachytherapy for prostate cancer. Within thirty days, 576 (7.0%) patients experienced 686 hospital visits. Emergency department visits comprised the majority of the encounters (623 visits (79.8%), at a median time from surgery of 5 days (IQR 1-13). Inpatient hospitalizations occured on 158 visits (20.2%) at a median 11 (IQR 5-20) days from surgery. Common presenting diagnoses included urinary retention n¼335 (42.9%), hematuria n¼59 (7.6%), and urinary tract infection n¼47 (6.0%). Logistic regression demonstrated that increasing patient age (65-75 years: OR 1.3 (95% CI 1.1-1.6); >75 years: OR 1.6 (95% CI 1.3-2.1)) and any inpatient admission within 90 days prior to surgery (OR 1.6 (95% CI 1.3-1.9) increased the risk of requiring hospital-based medical evaluation following outpatient brachytherapy. Baseline medical comorbidity (Charlson score) did not influence risk.
CONCLUSIONS: Emergency department visits and inpatient admissions are common following prostate brachytherapy, though at less frequent rates than previously reported. Risk of readmission is higher in elderly patients and those who have had recent inpatient hospitalizations.
Source of Funding: None

MP05-10 LONG-TERM URINARY SYMPTOMS FOLLOWING PROSTATE BRACHYTHERAPY
Nelson Stone*, Jared Winoker, New York, NY; Jamie Cavallo, New York, NM; Steven Kaplan, Richard Stock, New York, NY INTRODUCTION AND OBJECTIVES: Urinary symptoms in men who are treated with prostate brachytherapy (PSI) are known to worsen over time. We explored which patient and treatment related factors were associated with increased IPSS score in men who presented with minimal symptoms prior to treatment.
METHODS: Of 1981 men followed a minimum 5 years (mean 10, range 5-22), 1842 (93%) had pre-implant and last IPSS. 1110 (60.3%) had minimal initial urinary symptoms (score of 0-7). There were 491 (44.2%) low risk men treated with PSI alone or with 3-6 months of neoadjuvant hormone therapy (NHT) for prostate size > 50cc, 218 (19.6%) intermediate risk men treated with PSI plus NHT, or 76 (6.8%) with external beam irradiation (45 Gy EBRT) and 325 (29.4%) high risk treated by PSI/NHT/ EBRT. NHT was given a median of 9 months. Median prostate volume (PV) was 37 cc (range 2.4-188.1). Data was prospectively collected on comorbidities. Radiation dose was converted to the biological effective dose (BED). Initial IPSS was compared to last by student-t test (2 tailed). Survival estimates for minimal symptoms increasing to moderate or severe were determined by Kaplan-Meier method with comparisons by log rank and Cox Hazard Rates (HR).
RESULTS: The change from pre-treatment score to last IPSS score for the minimal, moderate and severe symptoms was: 3.6 to 7.3 (p<0.001), 11.6 to 11.3 (p¼0.426) and 24.1 to 16.9 (p<0.001). For those with minimal symptoms the 10 and 15 year estimates for freedom from worse symptoms were 72.9 and 39.1%, respectively. The 10 and 15 year estimates for pre-treatment and treatment related factors for freedom from increased IPSS are shown in the Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e41
